Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SHAK enters the November earnings window with an unusual split: short sellers have been retreating for weeks, yet options traders remain more cautious than the stock's 12% weekly gain might suggest.
The short side has been unwinding steadily. Short interest has dropped from roughly 3.95 million shares in early September to 3.27 million now, a fall of about 15% over the month, bringing SI to 8.1% of the free float. That is still a meaningful short position for a restaurant stock, but the direction is unambiguous: bears have been covering, not adding. The borrow market is loose. Availability is close to ten times the current short interest level, meaning there is no constraint on new shorts entering if sentiment turns. Cost to borrow is low at 0.52%, though it has risen 40% over the past week as the stock rallied. That uptick in borrow cost, from a very low base, reflects the price move more than any shift in conviction.
Options tell a less bullish story than the price action. The put/call ratio is 1.29, below its 20-day average of 1.41 and sitting about 1.1 standard deviations below that mean. That direction makes sense after an 11.6% week. Puts are still the dominant flow in absolute terms, the ratio has been above 1.0 for essentially the entire past month. The 52-week range runs from 0.86 to 1.61, and the current reading is closer to the low end, so options hedging has eased without disappearing. Taken together, positioning looks cautious but less crowded than it was: shorts have reduced, but the options market is not pricing a clean break higher.
The Street is broadly constructive but has been trimming targets. RBC Capital initiated with an Outperform at $89 in early September, and DA Davidson raised its target to $85 after the August results. But JP Morgan cut its target to $75 last week, keeping a Neutral rating, and several other firms lowered numbers over the summer while holding positive ratings. The mean target of around $80 implies roughly 24% upside to the current $64.61 price, which sounds generous, but the direction of travel on targets has been downward. Bears point to macro pressure on discretionary spending at premium price points, food cost inflation squeezing margins toward the lower end of EBITDA guidance, and cannibalization risk from the mid-teens unit growth plan. Bulls argue scale, a coming loyalty programme and better media spend can lift same-store sales, and that the brand's premium positioning supports pricing power. Valuation is not cheap: the stock trades on a trailing PE of roughly 48 times, and the EV/EBITDA multiple has been drifting up over the past month even as the price slid. The ORTEX short score has eased to 45.9 from a recent peak near 48, consistent with the short covering story, and ranks in the 34th percentile for bearish pressure in the sector.
The retail attention signal is worth a footnote: Wikipedia views for SHAK are running about 1.7 standard deviations above their 90-day average, a measure of retail interest rather than a revenue indicator, but it does suggest the stock has caught some attention during this week's bounce. The institutional register is dominated by passive holders, with BlackRock at 15.3% and two Vanguard entities each above 5%. Founder Daniel Meyer still holds a reported 4.1% as of June. None of the 13D/G register holders have filed activist intentions, and no open-market insider purchases appear in the recent EDGAR data, the June cluster was all stock grants.
The next print is November 5. The two most recent earnings reactions were a 6% gain and a 4% drop on the day, respectively, giving no consistent pattern. With short interest still at 8% of float and the stock now 7% below its one-month starting point despite this week's bounce, the November report is shaping up as the key test of whether the short cover was anticipatory or premature.
See the live data behind this article on ORTEX.
Open SHAK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
